Updates on Osteoporosis in Men.

Area of Science:

• Endocrinology
• Geriatrics
• Orthopedics

Background:

• Osteoporosis affects fewer men than women, but male patients have a higher mortality rate following major fragility fractures.
• Diagnosis typically relies on bone mineral density (BMD) or fragility fracture presence, particularly of the spine or hip.
• Many high-risk men may not meet the T-score threshold for osteoporosis diagnosis.

Purpose of the Study:

• To highlight the importance of comprehensive fracture risk assessment in men.
• To emphasize the utility of tools like FRAX (Fracture Risk Assessment Tool) for identifying at-risk individuals.
• To advocate for individualized pharmacologic management for men at high risk of fracture.

Main Methods:

• Review of current diagnostic criteria for osteoporosis in men.
• Evaluation of the role of bone mineral density (BMD) testing.
• Assessment of the utility of fracture risk assessment tools, such as FRAX.
• Discussion of therapeutic strategies for managing osteoporosis in men.

Main Results:

• Major fragility fractures carry a higher mortality risk in men compared to women.
• Bone mineral density (BMD) T-score criteria alone may underestimate fracture risk in many men.
• Fracture risk assessment tools, like FRAX, can identify men who require intervention despite not meeting BMD criteria.

Conclusions:

• A proactive approach combining BMD assessment and fracture risk calculation is essential for diagnosing osteoporosis in men.
• Pharmacological treatment with bone-active agents is recommended for men identified as high risk for fracture.
• Individualized treatment plans are necessary to effectively reduce fracture risk in the male population.